Search Results for 'patients ldl'

patients ldl published presentations and documents on DocSlides.

PCSK9 Inhibition: LDL Lowering

PCSK9 Inhibition: LDL Lowering

by SweetiePie

PCSK9 inhibitors. New option for dyslipidemia. Ali...

LDL Apheresis in Drug Resistant Nephrotic Syndrome

LDL Apheresis in Drug Resistant Nephrotic Syndrome

by obrien

Rodney D Gilbert. Patient JM. 14 year old girl, pr...

LDL is causal of atherosclerosis

LDL is causal of atherosclerosis

by morgan

Evidence from . meta-analyses of . Mendelian. . r...

Non-obese rheumatoid arthritis patients

Non-obese rheumatoid arthritis patients

by valerie

withlow. low-density lipoprotein have higher coro...

The case for intensive lipid management:

The case for intensive lipid management:

by SillyGoose

The opportunities and issues for cardiologists. Pr...

CLEVELAND CLINIC JOURNAL OF MEDICINE VOLUME 73 NUMBER 1 J

CLEVELAND CLINIC JOURNAL OF MEDICINE VOLUME 73 NUMBER 1 J

by iris

CHRISTOPHER SIBLEY,MDDepartment of Cardiology,John...

THE MANAGEMENT OF DYSLIPIDEMIA Updated Version 20 150 2006

THE MANAGEMENT OF DYSLIPIDEMIA Updated Version 20 150 2006

by ariel

VA/DoD Clinical Practice Guideline Introduction ...

LDL Cholesterol Lowering with

LDL Cholesterol Lowering with

by shoffer

Evolocumab. and Outcomes in Patients with . Perip...

PCSK-9 Inhibitors Paul J

PCSK-9 Inhibitors Paul J

by tatyana-admore

PCSK-9 Inhibitors Paul J Kovack , DO, FACC, FACO...

LSU Journal Club Efficacy and Safety of

LSU Journal Club Efficacy and Safety of

by trish-goza

Evolocumab. in. Reducing Lipids and Cardiovascul...

Trial Design Evolocumab SC

Trial Design Evolocumab SC

by danika-pritchard

140 mg Q2W or 420 mg QM. Placebo SC. Q2W or QM. L...

FOURIER F urther cardiovascular

FOURIER F urther cardiovascular

by trish-goza

OU. tcomes. . R. esearch with PCSK9 . I. nhibiti...

협심증 ( 狹心症 )

by lois-ondreau

Kyung Woo Park, MD, PhD, MBA . Seoul National Uni...

Hypertension & Cholesterol

Hypertension & Cholesterol

by cheryl-pisano

Blake Wachter, MD, PhD. Idaho Heart Institute. Ep...

Novel therapies for the prevention of atherosclerotic vascu

Novel therapies for the prevention of atherosclerotic vascu

by debby-jeon

Prof. . John . Kastelein. Academic Medical Centre...

Familial Hypercholesterolemia

Familial Hypercholesterolemia

by faustina-dinatale

KEY POINTS . FH is an autosomal dominant genetic...

D yslipidemia DR,DUAA HIASAT

D yslipidemia DR,DUAA HIASAT

by mackenzie

Objectives :. Know the clinical terminology for ...

Hypolipidemic drugs Shaymaa F. Abbas

Hypolipidemic drugs Shaymaa F. Abbas

by norah

Pharmacology Department. 24 SLIDES. 1. Learning ob...

Putting Your Skills to the Test

Putting Your Skills to the Test

by deborah

Which ONE of the following statements regarding th...

CLINICAL PRACTICE

CLINICAL PRACTICE

by mia

USTRALIAN FAMILY Vol. 37, No. 7, July 2008 ichard ...

Management of Dyslipidaemia

Management of Dyslipidaemia

by anderson

July 2017 Edition of Clinical Practice Guidelines ...

The role of cholesteryl ester transfer protein TaqIB polymorphism in y

The role of cholesteryl ester transfer protein TaqIB polymorphism in y

by sophie

Bilal Ilanbey Meral Kayikcioglu Ebru Demirel Sez...

In The Name Of God Dyslipidemia

In The Name Of God Dyslipidemia

by PinkPandaBear

/Lipid management in . Diabetes. Dr.Zahra. . davo...

Diabetic dyslipidemia : The pro-

Diabetic dyslipidemia : The pro-

by deborah

atherogenic. role of CETP and future use of CETP ...

Drugs of hyperlipidemia

Drugs of hyperlipidemia

by eve

. 4. th. Stage . Dr. Dalia . Abd. Al- Kader. PhD...

DYSLIPIDEMIA IN DIABETES

DYSLIPIDEMIA IN DIABETES

by esther

MAHTAB NIROOMAND M.D.. Assistant professor of End...

The New Cholesterol Guidelines:

The New Cholesterol Guidelines:

by lily

Beauty is in the Eye of the Beholder. Brian Asbill...

Rational Order of Laboratory Tests in Cardiovascular Diseases

Rational Order of Laboratory Tests in Cardiovascular Diseases

by carneos

Sedighe. . S. adat . Ghorashi. . MD. Family Medic...

Protecting the heart and the kidney:

Protecting the heart and the kidney:

by pressio

Implications from the SHARP trial. Dr. Christina R...

Management of Common Comorbidities in Diabetes

Management of Common Comorbidities in Diabetes

by celsa-spraggs

1. Obesity. Management of Common Comorbidities in...

The Importance of Potential

The Importance of Potential

by pamella-moone

Statin. in High Risk Patient. Masrul Syafri. Bag...

Cholesterol-Lowering Drugs

Cholesterol-Lowering Drugs

by cheryl-pisano

Victor Nadler. Objectives. By the end of this cla...

Update: Lipid Guidelines

Update: Lipid Guidelines

by yoshiko-marsland

DO NOT BURN THE COOKIES. Amy R. Woods, M.D.. a. ...

by olivia-moreira

Dyslipidemia. . Treatment. USA-145-101385. © . ...

DIABETES AND LIPID

DIABETES AND LIPID

by yoshiko-marsland

S-KHALILZADEH. Lipids are hydrophobic molecules t...

Protecting the heart and the kidney:

Protecting the heart and the kidney:

by marina-yarberry

Implications from the SHARP trial. Dr. Christina ...

D yslipidemia Objectives :

D yslipidemia Objectives :

by arya

Know the clinical terminology for . dyslipidemia...

Drug Therapies Post Acute Coronary Syndrome Event

Drug Therapies Post Acute Coronary Syndrome Event

by phoebe

Prof. Dr. . Kurt Huber. , MD. Sigmund Freud Univer...

CSL 112 (Apolipoprotein A-I) Infusions and Cardiovascular Outcomes in Patients With Acute Myocardia

CSL 112 (Apolipoprotein A-I) Infusions and Cardiovascular Outcomes in Patients With Acute Myocardia

by lucy

A. poA-I . E. vent Reducin. G. in . I. schemic . ...

Novel therapies for the prevention of atherosclerotic vascular disease

Novel therapies for the prevention of atherosclerotic vascular disease

by risilvia

John Kastelein, MD . Academic Medical Centre. Amst...